title: miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment.
abstract: In adoptive T cell transfer therapy (ACT), the antitumor efficacy of cytotoxic CD8+T lymphocytes (CTLs) has been limited by tumor-induced immunosuppression. We have demonstrated that miR-23a blockade in tumor-specific CTLs conferred resilience to TGFβ-mediated immunosuppression, resulting in superior tumor control. Our studies highlight miR-23a in tumor-specific CTLs as a clinically relevant target to enhance ACT.
authors.affiliation: Department of Immunology; Duke University Medical Center ; Durham, NC, USA.
authors.forename: Regina
authors.initials: R
authors.lastname: Lin
authors.affiliation: Department of Immunology; Duke University Medical Center ; Durham, NC, USA ; Department of Neurosurgery; Duke University Medical Center ; Durham, NC, USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
authors.affiliation: Department of Immunology; Duke University Medical Center ; Durham, NC, USA.
authors.forename: Qi-Jing
authors.initials: QJ
authors.lastname: Li
authors.affiliation: Institute of Cancer; Xinqiao Hospital ; The Third Military Medical University ; Chongqing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhu
keywords: TGFβ; cancer immunotherapy; cytotoxic CD8+ T lymphocytes; immune evasion; microRNA